|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPS15 |
Gene summary for RPS15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPS15 | Gene ID | 6209 |
| Gene name | ribosomal protein S15 | |
| Gene Alias | RIG | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000028 | UniProtAcc | P62841 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6209 | RPS15 | GSM4909280 | Human | Breast | Precancer | 7.05e-03 | -3.18e-01 | 0.0305 |
| 6209 | RPS15 | GSM4909281 | Human | Breast | IDC | 1.05e-09 | -1.47e-01 | 0.21 |
| 6209 | RPS15 | GSM4909282 | Human | Breast | IDC | 1.08e-54 | -3.14e-01 | -0.0288 |
| 6209 | RPS15 | GSM4909285 | Human | Breast | IDC | 9.35e-56 | -3.18e-01 | 0.21 |
| 6209 | RPS15 | GSM4909286 | Human | Breast | IDC | 1.04e-12 | 1.27e-01 | 0.1081 |
| 6209 | RPS15 | GSM4909287 | Human | Breast | IDC | 9.13e-10 | -1.99e-01 | 0.2057 |
| 6209 | RPS15 | GSM4909290 | Human | Breast | IDC | 2.31e-02 | 7.62e-02 | 0.2096 |
| 6209 | RPS15 | GSM4909291 | Human | Breast | IDC | 2.45e-21 | 1.80e-01 | 0.1753 |
| 6209 | RPS15 | GSM4909293 | Human | Breast | IDC | 2.73e-32 | -1.98e-01 | 0.1581 |
| 6209 | RPS15 | GSM4909295 | Human | Breast | IDC | 3.49e-12 | -2.85e-01 | 0.0898 |
| 6209 | RPS15 | GSM4909296 | Human | Breast | IDC | 7.81e-20 | 1.74e-01 | 0.1524 |
| 6209 | RPS15 | GSM4909301 | Human | Breast | IDC | 7.61e-18 | 1.44e-01 | 0.1577 |
| 6209 | RPS15 | GSM4909302 | Human | Breast | IDC | 3.63e-02 | 5.22e-02 | 0.1545 |
| 6209 | RPS15 | GSM4909304 | Human | Breast | IDC | 2.55e-06 | 9.76e-02 | 0.1636 |
| 6209 | RPS15 | GSM4909306 | Human | Breast | IDC | 7.91e-06 | 9.77e-02 | 0.1564 |
| 6209 | RPS15 | GSM4909307 | Human | Breast | IDC | 9.18e-06 | 1.03e-01 | 0.1569 |
| 6209 | RPS15 | GSM4909308 | Human | Breast | IDC | 1.37e-04 | 7.38e-02 | 0.158 |
| 6209 | RPS15 | GSM4909311 | Human | Breast | IDC | 3.68e-23 | 1.64e-01 | 0.1534 |
| 6209 | RPS15 | GSM4909312 | Human | Breast | IDC | 3.77e-08 | 1.03e-01 | 0.1552 |
| 6209 | RPS15 | GSM4909315 | Human | Breast | IDC | 2.23e-03 | -1.46e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000188921 | Stomach | CSG | liver development | 19/1034 | 147/18723 | 4.78e-04 | 7.42e-03 | 19 |
| GO:006100821 | Stomach | CSG | hepaticobiliary system development | 19/1034 | 150/18723 | 6.16e-04 | 8.96e-03 | 19 |
| GO:00096152 | Stomach | CSG | response to virus | 36/1034 | 367/18723 | 6.16e-04 | 8.96e-03 | 36 |
| GO:005116821 | Stomach | CSG | nuclear export | 19/1034 | 154/18723 | 8.52e-04 | 1.15e-02 | 19 |
| GO:190179621 | Stomach | CSG | regulation of signal transduction by p53 class mediator | 13/1034 | 93/18723 | 1.76e-03 | 1.90e-02 | 13 |
| GO:000691311 | Stomach | CSG | nucleocytoplasmic transport | 28/1034 | 301/18723 | 4.97e-03 | 4.10e-02 | 28 |
| GO:005116911 | Stomach | CSG | nuclear transport | 28/1034 | 301/18723 | 4.97e-03 | 4.10e-02 | 28 |
| GO:00000541 | Stomach | CSG | ribosomal subunit export from nucleus | 4/1034 | 14/18723 | 5.93e-03 | 4.66e-02 | 4 |
| GO:00337501 | Stomach | CSG | ribosome localization | 4/1034 | 14/18723 | 5.93e-03 | 4.66e-02 | 4 |
| GO:00160723 | Stomach | CSG | rRNA metabolic process | 23/1034 | 236/18723 | 5.96e-03 | 4.68e-02 | 23 |
| GO:000218131 | Stomach | CAG | cytoplasmic translation | 60/552 | 148/18723 | 9.60e-53 | 4.29e-49 | 60 |
| GO:004225531 | Stomach | CAG | ribosome assembly | 14/552 | 61/18723 | 2.00e-09 | 3.66e-07 | 14 |
| GO:002261331 | Stomach | CAG | ribonucleoprotein complex biogenesis | 39/552 | 463/18723 | 4.33e-09 | 6.72e-07 | 39 |
| GO:004225431 | Stomach | CAG | ribosome biogenesis | 29/552 | 299/18723 | 2.08e-08 | 2.58e-06 | 29 |
| GO:004227431 | Stomach | CAG | ribosomal small subunit biogenesis | 14/552 | 73/18723 | 2.38e-08 | 2.87e-06 | 14 |
| GO:000002831 | Stomach | CAG | ribosomal small subunit assembly | 8/552 | 19/18723 | 3.08e-08 | 3.52e-06 | 8 |
| GO:002261831 | Stomach | CAG | ribonucleoprotein complex assembly | 24/552 | 220/18723 | 3.77e-08 | 4.21e-06 | 24 |
| GO:007182631 | Stomach | CAG | ribonucleoprotein complex subunit organization | 24/552 | 227/18723 | 6.88e-08 | 7.14e-06 | 24 |
| GO:190332131 | Stomach | CAG | negative regulation of protein modification by small protein conjugation or removal | 15/552 | 95/18723 | 1.15e-07 | 1.09e-05 | 15 |
| GO:003139731 | Stomach | CAG | negative regulation of protein ubiquitination | 14/552 | 83/18723 | 1.30e-07 | 1.18e-05 | 14 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPS15 | SNV | Missense_Mutation | rs746003968 | c.185C>T | p.Ser62Phe | p.S62F | protein_coding | tolerated(0.2) | benign(0.445) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| RPS15 | SNV | Missense_Mutation | c.185C>G | p.Ser62Cys | p.S62C | protein_coding | tolerated(0.05) | benign(0.045) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| RPS15 | insertion | Frame_Shift_Ins | novel | c.187_188insGCGGCTTAGT | p.Leu63ArgfsTer? | p.L63Rfs*? | protein_coding | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| RPS15 | SNV | Missense_Mutation | novel | c.373G>A | p.Glu125Lys | p.E125K | protein_coding | deleterious(0.04) | benign(0.093) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPS15 | SNV | Missense_Mutation | c.172N>T | p.Arg58Trp | p.R58W | protein_coding | deleterious(0.05) | benign(0.048) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| RPS15 | SNV | Missense_Mutation | novel | c.430N>A | p.His144Asn | p.H144N | protein_coding | tolerated(0.09) | possibly_damaging(0.514) | TCGA-AX-A3FS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPS15 | SNV | Missense_Mutation | c.263G>A | p.Arg88Gln | p.R88Q | protein_coding | deleterious(0.04) | benign(0.041) | TCGA-55-1592-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| RPS15 | SNV | Missense_Mutation | c.451C>G | p.Leu151Val | p.L151V | protein_coding | deleterious(0.02) | possibly_damaging(0.801) | TCGA-55-A48Y-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR | ||
| RPS15 | SNV | Missense_Mutation | novel | c.415N>A | p.Gly139Ser | p.G139S | protein_coding | deleterious(0.03) | benign(0.141) | TCGA-B7-A5TJ-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |